{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:21:53Z","timestamp":1791994913719,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11906-005-0012-5","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T06:03:23Z","timestamp":1180073003000},"page":"206-211","source":"Crossref","is-referenced-by-count":5,"title":["Aldosterone receptor antagonists: Biology and novel therapeutic applications"],"prefix":"10.1007","volume":"7","author":[{"given":"Paolo","family":"Magni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"12_CR1","first-page":"S14","volume":"26","author":"X Jeunemaitre","year":"1988","unstructured":"Jeunemaitre X, Kreft-Jais C, Chatellier G, et al.: Long-term experience of spironolactone in essential hypertension. Kidney Int Suppl 1988, 26:S14-S17.","journal-title":"Kidney Int Suppl"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0039-128X(94)00012-2","volume":"60","author":"N Glorioso","year":"1995","unstructured":"Glorioso N, Tonolo G, Troffa C, et al.: Recognition of markers of response to potassium-canrenoate in essential hypertension. Steroids 1995, 60:105\u2013109.","journal-title":"Steroids"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/08037059209077510","volume":"1","author":"SE Campbell","year":"1992","unstructured":"Campbell SE, Diaz-Arias AA, Weber KT: Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press 1992, 1:149\u2013156.","journal-title":"Blood Press"},{"key":"12_CR4","first-page":"E883","volume":"271","author":"MJ Young","year":"1996","unstructured":"Young MJ, Funder JW: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996, 271:E883-E888.","journal-title":"Am J Physiol"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730\u20131736.","journal-title":"Circulation"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"17A","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez DA, Bauwens FR, De Buyzere ML, et al.: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993, 71:17A-20A.","journal-title":"Am J Cardiol"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","volume":"15","author":"B Pitt","year":"2001","unstructured":"Pitt B, Williams G, Remme W, et al.: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79\u201387.","journal-title":"Cardiovasc Drugs Ther"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. One of the reports on the important EPHESUS study, showing the advantage of the addition of eplerenone to current cardiovascular therapy in MI and HF.","journal-title":"N Engl J Med"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijcard.2004.05.004","volume":"96","author":"LB Tan","year":"2004","unstructured":"Tan LB, Schlosshan D, Barker D: Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int J Cardiol 2004, 96:321\u2013333. An updated and comprehensive review on the role of aldosterone and ARAs in cardiovascular diseases.","journal-title":"Int J Cardiol"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","volume":"273","author":"JS Silvestre","year":"1998","unstructured":"Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 1998, 273:4883\u20134891.","journal-title":"J Biol Chem"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/cs1020387","volume":"102","author":"AD Struthers","year":"2002","unstructured":"Struthers AD: Evidence for myocardial synthesis of aldosterone producing myocardial fibrosis in man. Clin Sci (Lond) 2002, 102:387.","journal-title":"Clin Sci (Lond)"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","volume":"269","author":"H Hatakeyama","year":"1994","unstructured":"Hatakeyama H, Miyamori I, Fujita T, et al.: Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316\u201324320.","journal-title":"J Biol Chem"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Cerelli G, et al.: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268\u2013275.","journal-title":"Science"},{"key":"12_CR15","first-page":"41","volume":"61","author":"M Lombes","year":"2000","unstructured":"Lombes M, Farman N, Bonvalet JP, Zennaro MC: Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris) 2000, 61:41\u201346.","journal-title":"Ann Endocrinol (Paris)"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0361-9230(01)00638-4","volume":"57","author":"C Kellendonk","year":"2002","unstructured":"Kellendonk C, Gass P, Kretz O, et al. Corticosteroid receptors in the brain: gene targeting studies. Brain Res Bull 2002, 57:73\u201383.","journal-title":"Brain Res Bull"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1016\/0303-7207(94)90027-2","volume":"99","author":"M Christ","year":"1994","unstructured":"Christ M, Sippel K, Eisen C, Wehling M: Non-classical receptors for aldosterone in plasma membranes from pig kidneys. Mol Cell Endocrinol 1994, 99:R31-R34.","journal-title":"Mol Cell Endocrinol"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","volume":"126","author":"CM Kagawa","year":"1957","unstructured":"Kagawa CM, Cella JA, Van Arman CG: Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt. Science 1957, 126:1015\u20131016.","journal-title":"Science"},{"key":"12_CR19","first-page":"249","volume":"8","author":"DD Fanestil","year":"1988","unstructured":"Fanestil DD: Mechanism of action of aldosterone blockers. Semin Nephrol 1988, 8:249\u2013263.","journal-title":"Semin Nephrol"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2265.1985.tb01090.x","volume":"23","author":"D Armanini","year":"1985","unstructured":"Armanini D, Karbowiak I, Goi A, et al.: In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 1985, 23:341\u2013347.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(85)92975-7","volume":"2","author":"A Dupont","year":"1985","unstructured":"Dupont A: Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Lancet 1985, 2:731.","journal-title":"Lancet"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","volume":"1","author":"EG McMahon","year":"2001","unstructured":"McMahon EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001, 1:190\u2013196.","journal-title":"Curr Opin Pharmacol"},{"key":"12_CR23","first-page":"650","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjoue HP, et al.: Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","volume":"32","author":"M de Gasparo","year":"1989","unstructured":"de Gasparo M, Whitebread SE, Preiswerk G, et al.: Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989, 32:223\u2013227.","journal-title":"J Steroid Biochem"},{"key":"12_CR25","first-page":"52","volume":"61","author":"F Mantero","year":"2000","unstructured":"Mantero F, Lucarelli G: Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000, 61:52\u201360.","journal-title":"Ann Endocrinol (Paris)"},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0039-128X(94)00018-8","volume":"60","author":"F Mantero","year":"1995","unstructured":"Mantero F, Opocher G, Rocco S, et al.: Long-term treatment of mineralocorticoid excess syndromes. Steroids 1995, 60:81\u201386.","journal-title":"Steroids"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:457\u2013465.","journal-title":"J Endocrinol"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056\u20131064.","journal-title":"Circulation"},{"key":"12_CR29","first-page":"1075","volume":"33","author":"M Epstein","year":"1999","unstructured":"Epstein M, Alexander J, Roniker B: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA) in patients with mild to moderate hypertension. Hypertension 1999, 33:1075.","journal-title":"Hypertension"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1161\/01.CIR.96.1.220","volume":"96","author":"AH Danser","year":"1997","unstructured":"Danser AH, van Kats JP, Verdouw PD, Schalekamp MA: Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 1997, 96:3795\u20133796.","journal-title":"Circulation"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1527-5299.2003.02397.x","volume":"9","author":"DA Sica","year":"2003","unstructured":"Sica DA, Gehr TW, Yancy C: Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail 2003, 9:224\u2013229.","journal-title":"Congest Heart Fail"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00045415-200203000-00008","volume":"10","author":"CT Stier Jr","year":"2002","unstructured":"Stier CT Jr, Chander PN, Rocha R: Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002, 10:97\u2013107.","journal-title":"Cardiol Rev"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","volume":"103","author":"Y Mizuno","year":"2001","unstructured":"Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72\u201377.","journal-title":"Circulation"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/cs1020381","volume":"102","author":"M Satoh","year":"2002","unstructured":"Satoh M, Nakamura M, Saitoh H, et al.: Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 2002, 102:381\u2013386.","journal-title":"Clin Sci (Lond)"},{"key":"12_CR35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","volume":"141","author":"MG Modena","year":"2001","unstructured":"Modena MG, Aveta P, Menozzi A, Rossi R: Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001, 141:41\u201346.","journal-title":"Am Heart J"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700\u20132706.","journal-title":"Circulation"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849\u20131865.","journal-title":"Circulation"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"12A","DOI":"10.1016\/0002-9149(93)90239-9","volume":"71","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993, 71:12A-16A.","journal-title":"Am J Cardiol"},{"key":"12_CR39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The Consensus Trial Study Group","year":"1987","unstructured":"The Consensus Trial Study Group: Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 1987, 316:1429\u20131435.","journal-title":"N Engl J Med"},{"key":"12_CR40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991, 325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"12_CR41","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","volume":"19","author":"P Vantrimpont","year":"1998","unstructured":"Vantrimpont P, Rouleau JL, Ciampi A, et al.: Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998, 19:1552\u20131563.","journal-title":"Eur Heart J"},{"key":"12_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","volume":"2","author":"AD Struthers","year":"1996","unstructured":"Struthers AD: Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996, 2:47\u201354.","journal-title":"J Card Fail"},{"key":"12_CR43","doi-asserted-by":"crossref","first-page":"34A","DOI":"10.1016\/0002-9149(93)90243-6","volume":"71","author":"F Zannad","year":"1993","unstructured":"Zannad F: Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am J Cardiol 1993, 71:34A-39A.","journal-title":"Am J Cardiol"},{"key":"12_CR44","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"12_CR45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","volume":"39","author":"DV Martinez","year":"2002","unstructured":"Martinez DV, Rocha R, Matsumura M, et al.: Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002, 39:614\u2013618.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0012-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-005-0012-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0012-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:54:47Z","timestamp":1628920487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-005-0012-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11906-005-0012-5","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}